Biography
Nick has a background in translational biomedical research and nanomaterials development. He is a Senior Lecturer in the School of Medical Science at the University of Sydney and a research leader at the ANZAC Research Institute, where his work focuses on nanotechnologies for clinical application, including drug, biologic, and gene therapy delivery.
Nick is Co-Founder and CEO of Endo Axiom, a clinical-stage biotechnology company whose investigational oral insulin programme entered Phase 1a first-in-human trials in September 2026. His research has been supported by the NHMRC, MRFF, and the University of Sydney.
Selected affiliations
- Chief Executive Officer Endo Axiom
